Compare Neurocrine Biosciences Inc (NBIX) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Occidental Petroleum Corporation — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Occidental Petroleum Corporation trades at $61.06 (market cap $60.63B). The key difference: Occidental Petroleum Corporation is far larger — about 3.8× Neurocrine Biosciences Inc's market cap, and Occidental Petroleum Corporation pays a 1.85% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | OXY | |
|---|---|---|
Market Cap | $15.77B | $60.63B |
Sector | Health | Energy |
52-Week High | $185.50 | $66.24 |
52-Week Low | $123.10 | $38.92 |
Enterprise Value | $15.78B | $79.39B |
Dividend Yield | — | 1.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Occidental Petroleum (OXY) trades at $60.65, up 1.02% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 30.32% net income margin and 21.46% ROE, while trading at reasonable valuations (P/E 17.89, EV/EBITDA 5.59). Recent earnings beats and improving balance sheet with debt reduction to $25.32 billion support positive sentiment.
OXY presents a compelling opportunity with analyst consensus target of $68.67 (13% upside) and 50% buy ratings. Key catalysts include continued debt reduction, projected 2026 net margin expansion to 30.31%, and oil price tailwinds. Risks include oil price volatility, execution on production targets, and macroeconomic headwinds affecting energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
